Today’s Time Capsule: Ships That Refuse to Stay Quiet

Today's Time Capsule  ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌

July 20, 2026   |   Read online A rare momentum indicator just fired — and it's pointing at a small-cap stock that's still flying completely under the radar. Historically, when this signal triggers, real movement tends to follow before the crowd ever catches on. Trading Ideas has put together the full briefing: company name, chart data, and the exact signal they're watching — all in one free report. This is the kind of early setup that doesn't stay quiet for long. Access the Free Report Now *We encourage readers to perform their own research and due diligence on any information we provide. By clicking the link you will automatically be subscribed to the Trading Ideas Newsletter. View our Privacy Policy. From Shackleton’s final vessel to a Swedish construction surprise and the Vikings at Paris’s gates, today’s news reminds us that waterways keep receipts—of ambition, commerce, and the politics that decide who gets protected. Image via Smithsonian Magazine Shackleton’s Last Ship, Now a Reef: The Quest’s New Life Comes With a Human Footprint New close-up images of Ernest Shackleton’s last ship, the Quest, show a wreck that feels like two stories layered on top of each other. The vessel, found in 2024 off northeastern Canada, now sits underwater like a reluctant museum exhibit: corals and anemones clinging to its surfaces, fish moving through its ribs, the whole structure transformed into habitat. It’s a reminder that shipwrecks don’t just end; they change jobs. But the photos also reveal something less romantic: discarded fishing gear draped across the wreckage, leftovers of decades of commercial activity. That contrast is the modern era in one frame—nature reclaiming, industry lingering. Historically, maritime sites have always been crossroads of memory and economy. We like to imagine polar exploration as a sealed-off chapter of heroism, but the ocean keeps merging chapters together: exploration, extraction, accident, and now ecology, all occupying the same coordinates. The Quest’s afterlife also echoes a familiar pattern in preservation: what we “discover” is often what local communities and working industries have been navigating for years. Close-up documentation can protect a site, but it can also spotlight how vulnerable underwater heritage is to the everyday business of the sea. The wreck is teaching the same lesson shipwrecks have taught for centuries—water preserves, but it also entangles. Read the full story at Smithsonian Magazine → Image via Popular Mechanics Six Shipwrecks Under a Worksite: Sweden’s Waterfront Turns Out to Be a Time Machine Construction workers in Sweden made the kind of discovery that rearranges a map in your head: not one shipwreck, not two, but six. Dating from the 17th century and reaching back as far as the medieval era, the wrecks suggest a shoreline that has been busy, risky, and strategically important for a very long time. It’s the maritime version of digging a garden and hitting an entire layered city. This is how port history often reveals itself—not in tidy timelines, but in clusters. A single wreck can be a storm story, a navigation mistake, a battle, a fire, or a bureaucratic failure. Six wrecks in one area hints at repeated traffic, repeated hazard, and repeated rebuilding. In early modern and medieval Europe, ships were infrastructure as much as vehicles. They carried the taxes, the grain, the timber, the soldiers, the news. When they went down, it wasn’t just a loss of property; it was a disruption in the bloodstream of the state. There’s also something wonderfully humbling about the setting: a modern worksite exposing the logistical backbone of earlier centuries. Many of us learned history as palaces and parliaments. Wrecks like these push the story back to the waterfront, where ordinary labor, trade regulations, and hard weather decided what a kingdom could afford to do next. Read the full story at Popular Mechanics → Why Paris Fell Under Viking Pressure Twice: A Lesson in Division, Leverage, and the River The Viking sieges of Paris in the ninth century weren’t just a tale of fearless raiders meeting a brave city. As Danielle Turner explains, the Vikings were able to press Paris twice because of a potent mix of political division, strategy, and choices made by leaders who didn’t always pull in the same direction. The Vikings understood something basic and enduring: you don’t need to conquer every mile of territory if you can control the chokepoints. Paris’s geography mattered. The Seine was a highway, and the city’s position made it both valuable and vulnerable. Viking forces could move quickly by river, threaten commerce, and apply pressure where defenses were strongest on paper but weakest in coordination. The story turns, in part, on whether surrounding powers would unify to relieve the city—or calculate that someone else should pay the price. Medieval politics could be intensely local, and that localism could be fatal when a fast-moving external threat arrived. What makes these sieges feel strikingly modern is how much of the outcome hinged on political will and negotiated decisions rather than sheer battlefield dominance. The Vikings weren’t only testing walls; they were testing alliances, incentives, and the speed of response. The lesson is less “raiders were unstoppable” and more “fractured leadership invites specialists in exploitation,” especially when a river delivers them straight to your front door. Read the full story at Medievalists.net → That’s today’s capsule. If you find yourself near a river or a harbor this week, pause for a second: chances are you’re standing beside an old argument between commerce and security, memory and forgetting—and the water remembers how it played out. — Time Capsule Editorial 🕰️ Don't Miss a Beat Get exclusive history stories & subscriber-only offers sent straight to your phone. Text-only extras you won't find in the newsletter. Join Our SMS List → Update your email preferences or unsubscribe here © 2026 List Growth Solutions LLC 924 N Magnolia Ave, Suite 202, Unit #5291 Orlando, Florida 32803, United States Terms of Service

A Small Defense Firm Is Targeting a Critical Battlefield Gap

A small defense firm is combining AI, autonomous systems, and advanced sensing to address tomorrow’s battlefield threats.  ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌

Unsubscribe   A Message from Equiscreen Dear Investor, Wars are no longer won by firepower alone. The advantage now belongs to systems that can detect a threat, analyze it, and respond before the enemy has time to react. One small defense technology firm is building directly into that shift. Its platform combines artificial intelligence, advanced sensing, autonomous systems, and real-time analytics within one operating architecture. Several developments are putting this emerging company on investors’ radar: New patent initiatives designed to protect its defense technology Expanded radio-frequency sensing capabilities Acquired computer-vision assets that could strengthen its AI platform Technologies built for defense, homeland security, and threat detection Exposure to rising demand for drones and rapid-response systems The company is still early. That comes with risk. But governments are spending heavily on technology that can identify and respond to modern threats faster. Companies that solve that problem could become increasingly important across the defense supply chain. This story remains under the radar, but that may not last as its technology and intellectual property portfolio expand. See why this emerging defense company is starting to attract attention.     PAID ADVERTISEMENT — COST-PER-CLICK COMPENSATION This email is a paid advertisement and is not editorial content. Elite Trade Club ("ETC") has been compensated on a cost-per-click ("CPC") basis for the dissemination of information about the company referenced herein. Because ETC is paid for each click generated by this advertisement, ETC has a direct financial incentive to encourage you to click on links contained herein. The total compensation received by ETC is unknown at the time of distribution and depends entirely on reader engagement. This creates a material conflict of interest. The paying party and/or its affiliates, officers, or agents may hold shares of the featured company and may sell some or all of those shares during or after this campaign, which could negatively impact the share price. This is not financial advice. ETC has not performed due diligence on the featured company and makes no representations regarding the accuracy or completeness of the information provided. Any forward-looking statements are speculative and subject to risks that could cause actual results to differ materially. Do not make investment decisions based on this advertisement. Consult a licensed financial advisor before purchasing any securities. This notice is provided in compliance with Section 17(b) of the Securities Act of 1933. © 2026 Elite Trade Club. All rights reserved. Privacy Policy | Terms of Service | Advertise Update your email preferences or unsubscribe here © 2026 Elite Trade Media LLC 1969 Alafaya Tr., Suite #247 Orlando, Florida 32828, United States Terms of Service

BREAKING: Michigan AD Warde Manuel to step down

View in browser  Breaking News Breaking News Michigan athletic director Warde Manuel stepping down Read Full Story 2026 Big Ten College Football Preview: CFP favorites, power rankings, more READ STORY > College football schedule superlatives for 2026: Easiest, toughest and everything in between READ STORY > 2026 Big Ten College Football Preview: CFP favorites, power rankings, more READ STORY > College football schedule superlatives for 2026: Easiest, toughest and everything in between READ STORY > Join the On3 community and unlock access to every premium article across the network. Join On3 Get The App Unsubscribe Privacy Policy On3.com © 2026 On3 | Rivals. All rights reserved. 2970 Foster Creighton Drive, Nashville, TN 37204

(NYSE American: VNRX) Entered A Key Collab That Could Target Disruption Of A $3.8Bn TAM

Friday's profile went hard early after the morning bell.

Any content you receive is for information purposes only. Always conduct your own research. *Sponsored (NYSE American: VNRX) Entered A Key Collab That Could Target Disruption Of A $3.8Bn TAM *Click Here To Get Our Alerts Faster Via SMS* July 20th Greetings Readers, Friday's profile went hard early after the morning bell. Moving from an open of $1.35, it shot quickly to a high of $1.76 in the blink of an eye. Overall, that early surge resulted in a run of approx. 30% intraday. At the same time, we started zeroing in on a new idea... There’s a heal-thcare diagnostics company drawing attention for its work in earlier disease detection and treatment monitoring, using blood-based science that could reshape how clinicians spot serious conditions sooner. It has been broadening its reach through new studies, product launches, and partnerships, while continuing to push beyond a single-use approach. Recent updates suggest a mix of commercial progress, scientific validation, and practical real-world applications that make it worth taking a closer look. For anyone following innovation in precision medicine, this is one of those names that deserves a second glance. And with a low float, a strong analyst target pointing to potential quadruple-digit upside, and key oversold leaning technicals, this NYSE American profile tops our Monday watchlist: VolitionRx Limited (NYSE American: VNRX) Volition is a multi-national company focused on advancing the science of epigenetics. Volition is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring. And based on multiple potential catalysts, (NYSE American: VNRX) has taken over the top spot on our watchlist. Check them out: #1. A Significant Analyst Target ($16.83) May Signal Quadruple-Digit Potential Upside. #2. A Low Float Under 7Mn Shares May Create A Potential Environment For Heightened Volatility. #3. The Company Demonstrates Significant Value Of Its Nu.Q® Cancer Assay With The Release Of Data From A New Clinical Study. #4. A Collaboration With A Global Leader In Vitro Diagnostics Could Help Target Disruption Of A $3.8Bn TAM. #5. Key Oversold Leaning Technical Indicators Could Suggest A Healthy Reversal May Be Nearing. But more on those in a second... Complete Company Overview - VolitionRx Limited Through its subsidiaries, Volition is developing and commercializing simple, easy to use, cost-effective blood tests to help diagnose and monitor a range of diseases, including some cancers and diseases associated with NETosis, such as sepsis. Early diagnosis and monitoring have the potential not only to prolong the life of patients, but also improve their quality of life. Volition's research and development activities are centered in Belgium, with an innovation laboratory and office in the U.S. and additional offices in London and Singapore. Early Diagnosis Saves Lives Imagine a world where diseases like cancer and sepsis can be diagnosed early and monitored easily using routine blood tests. That’s the world Volition is trying to build by developing their innovative family of simple, easy to use, cost-effective tests. Their patented technologies use chromosomal structures such as nucleosomes and transcription factors as biomarkers in cancer and other diseases. All the tests in their portfolio detect various characteristic changes that occur from the earliest stages of disease, enabling early detection and potentially a better way to monitor disease progression and a patient’s response to treatment. Nu.Q® Technology The Company's patented Nucleosomics™ technology isolates circulating nucleosomes from the blood for quantification and analysis, to enable earlier diagnosis and monitoring of life-altering diseases. Patented Nucleosomics™ technology Their patented Nucleosomics™ technology isolates circulating nucleosomes from the blood for quantification and analysis. Based on this core, cutting-edge technology they have developed a portfolio of Nu.Q® assays which are simple, low-cost, accessible, routine blood tests. Their tests are platform agnostic so can be adapted to any workflow setting – manual, reference laboratory and point-of-care. The Company's technology detects characteristic epigenetic changes in nucleosomes that occur from the earliest stages of disease enabling early detection and potentially a better way to monitor disease progression and a patient’s response to treatment. Epigenetic changes can be detected before the diseased cells themselves become abnormal enough to show up in traditional biopsies, and oftentimes before the first symptoms are felt. Volition aims to replace unpleasant, invasive, and often expensive screening and diagnostic tests with Nu.Q® blood tests, helping to save lives and to reduce overall heal-th care costs. Commercialization Strategy Underlying principles: low capex, low opex business model focused on commercial partnerships and outlicensing R&D -- R&D conducted by Volition and its research partners -- Monetize IP through licensing agreements with: upfront payments, milestone payments, recurring revenue from sales of key components & royalties Licensing and partnering criteria: -- Broad geographic reach -- Large installed base -- Experience of tech transfer -- Regulatory and clinical affairs -- Large sales and marketing teams 2026: Targeting multiple licensing deals in the human space Pioneering Liquid Biopsy Solving the "Needle in a Haystack" Problem One of the primary hurdles in liquid biopsy is the difficulty of detecting rare circulating tumor DNA (ctDNA) amidst a sea of healthy DNA. In December 2025, VNRX announced a technological breakthrough involving its Nu.Q® Capture technology. The company achieved a 180-fold (18,000%) enrichment of tumor-derived DNA. This advancement significantly enhances the sensitivity of sequencing, potentially allowing for the detection of cancer at much earlier stages when treatment is most effective. Strategic Expansion into Acute Care Beyond chronic disease, VNRX is targeting the high-stakes environment of intensive care units. The company's Nu.Q® NETs assay has been included in a major real-world evaluation in France for the early detection of sepsis. Sepsis is a leading cause of hospital mortality, and the ability to quantify Neutrophil Extracellular Traps (NETs) could provide doctors with a critical tool to identify at-risk patients hours or even days earlier than current methods. Robust Intellectual Property and Pipeline The company’s growth is underpinned by an extensive patent portfolio covering its nucleosome detection methods. Volition Overall Highlights Multiple products already launched Proven Licensing model, validated in Vet Strong IP Multiple multi-Bn dollar TAM markets Low-cost, scalable platform with high margins Asset light - no need for their machines, labs, or sales reps In confidential licensing discussions with more than a dozen large diagnostic and liquid biopsy companies worldwide, first deals signed in Q3 2025 Anticipate use in routine clinical practice in 2026 Grab Sources And More Here: VNRX Website. VNRX Presentation. ----- And as I mentioned earlier, (NYSE American: VNRX) has several potential catalysts of focus. Take a look: #1. VNRX Potential Catalyst - A Significant Analyst Target ($16.83) May Signal Quadruple-Digit Potential Upside. Back in April, Zacks Small-Cap Research analyst, Steven Ralston, provided an update to coverage on (NYSE American: VNRX) with a price target of $16.83. From Friday's closing valuation, this target suggests a potential upside of 1,430%. Here's some report highlights: Valuation Utilizing a financial model based on DCF methodology, which forecasts out to 2033, and uses a 10% discount rate (based on CAPM), a 2% terminal growth rate and a terminal P/S multiple of 0.56, the indicated value of VNRX is $16.83 per share. The predominate factor for the lower target is the dilution resulting from the issuance of the Lind Global Asset Management XII LLC Notes (in 2025 and 2026). ----- #2. VNRX Potential Catalyst - A Low Float Under 7Mn Shares May Create A Potential Environment For Heightened Volatility. According to info from the Yahoo Finance website, VNRX has a low float. The website reports this profile to have roughly 6.66Mn shares in its float. Why is that important? It's important on one crucial level. Volatility potential. If the company provides positive news during the 2nd half of 2026, could it help provide a breakout spark when paired with this volatility potential? ----- #3. VNRX Potential Catalyst - The Company Demonstrates Significant Value Of Its Nu.Q® Cancer Assay With The Release Of Data From A New Clinical Study. VolitionRx Announces Data Showing the Prognostic Value of its Nu.Q® Cancer Test HENDERSON, Nev., July 7, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces the release of a new clinical study demonstrating the significant prognostic value of its Nu.Q® Cancer Assay in newly diagnosed lung cancer patients, which could help clinicians identify patients' likely outcomes and personalize treatment selection accordingly. The clinical paper entitled "Prognostic value of circulating H3K27Me3-nucleosomes in newly diagnosed lung cancer patients: Real-world evidence1" has been written in conjunction with researchers and clinicians at the Hospices Civils de Lyon (HCL), France's second largest university hospital system, and is currently under peer review. Dr Andrew Retter, Medical Consultant, Volition said: "Nu.Q® Cancer represents a significant advancement in lung cancer patient management, offering clinicians an additional tool to enhance precision in treatment selection and monitoring and is a test we envisage will be used routinely in the clinic once approved. We have worked closely with the Lyon team over several years to develop the strong scientific and clinical evidence to support the use of Nu.Q® in the management of cancer patients. These results indicate that measuring methylated nucleosome biomarker levels with the Nu.Q® test, at Non Small Cell Lung Cancer diagnosis, can provide valuable information about survival, progression-free survival and, crucially, enhance the identification of patients who may benefit from curative care. The integration of epigenetic biomarkers, such as circulating H3K27Me3-nucleosome, into personalized medicine frameworks holds great promise for refining patient stratification and treatment selection. The test is simple to complete and easy to implement, the new information helps to empower bedside clinicians and their patients to make better informed decisions on treatments and planning future care together." ... Read the full article here. ----- #4. VNRX Potential Catalyst - A Collaboration With A Global Leader In Vitro Diagnostics Could Help Target Disruption Of A $3.8Bn TAM. VolitionRx Announces Collaboration with Sysmex HENDERSON, Nev., June 17, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announces a collaboration with Sysmex (TYO: 6869), a leader in global in vitro diagnostics, to optimize Volition's Nu.Q® NETs H3.1 assay on the Sysmex platform. Gael Forterre, Chief Commercial Officer, Volition commented: "We are proud to have entered into this agreement with Sysmex, as we implement our strategy to out license our proprietary Nu.Q® NETs test to large companies with a worldwide presence, to leverage their knowledge of specific diseases, product development, regulatory experience and their installed base of proprietary analyzers. Sysmex is a global leader in the field of in vitro diagnostics for hemostasis and thrombosis, among other diseases, where Neutrophil Extracellular Traps ("NETS") play such an important role. Following the successful transfer of our Nu.Q® NETs assay onto Sysmex's platform we are delighted to commence the optimization phase in diseases associated with NETosis. NETosis is implicated in a wide range of diseases, including sepsis and other acute and chronic diseases. We believe that Volition's Nu.Q® NETs test could provide not only improved diagnostic information to aid clinical decision-making and personalized care, but could also be a low-cost test to continue to monitor a patient's condition. The commercial opp. for the Nu.Q® NETs assay is significant, with a Total Addressable Market of $3.8Bn. It is exciting to progress the collaboration with Sysmex and we look forward to a fruitful long-term partnership together." ... Read the full article here. ----- #5. VNRX Potential Catalyst - Key Oversold Leaning Technical Indicators Could Suggest A Healthy Reversal May Be Nearing. At 4:00PM EST Friday, Barchart was reporting VNRX to have several oversold leaning technical indicators. These technicals could be signaling a healthy reversal is approaching in the near term. Here's the definition of a "reversal" from Investopedia: "A reversal is a change in the price direction of an asset. A reversal can occur to the upside or downside. Following an uptrend, a reversal would be to the downside. Following a downtrend, a reversal would be to the upside. Reversals are based on overall price direction and are not typically based on one or two periods/bars on a chart." Here are the technicals to pay close attention to (as of 4:00PM EST Friday): 9-Day Relative Strength Index: 24.06% 14-Day Relative Strength Index: 29.30% When these numbers drop down to the 30% range and lower, they can be viewed as being in oversold territory. While in this territory, they can paint the picture of a profile that is undervalued. Keep an eye on these technicals closely. ----- (NYSE American: VNRX) Recap - 5 Potential Catalysts On Watch #1. A Significant Analyst Target ($16.83) May Signal Quadruple-Digit Potential Upside. #2. A Low Float Under 7Mn Shares May Create A Potential Environment For Heightened Volatility. #3. The Company Demonstrates Significant Value Of Its Nu.Q® Cancer Assay With The Release Of Data From A New Clinical Study. #4. A Collaboration With A Global Leader In Vitro Diagnostics Could Help Target Disruption Of A $3.8Bn TAM. #5. Key Oversold Leaning Technical Indicators Could Suggest A Healthy Reversal May Be Nearing. ----- Coverage is officially initiated on VolitionRx Limited (NYSE American: VNRX). Be on the lookout for updates heading out soon. Talk again shortly. Sincerely, Kai Parker StockWireNews (Always Remember The St-ock Prices Could Be Significantly Lower Now From The Dates I Provided.) *StockWireNews.com (“StockWireNews” or “SWN” ) is owned by SWN Media LLC, a single member limited liability company. Data is provided from third-party sources and SWN is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile SWN brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in-vest-ment advice, are not in-vest-ment advisors, and any profiles we mention are not suitable for all in-vest-ors. Pursuant to an agreement between SWN Media LLC and TD Media LLC, SWN Media LLC has been hired for a period beginning on 07/19/2026 and ending on 07/20/2026 to publicly disseminate information about (VNRX:US) via digital communications. Under this agreement, TD Media LLC has paid SWN Media LLC ten thousand USD ("Funds"). To date, including under the previously described agreement, SWN Media LLC has been paid forty seven thousand five hundred USD ("Funds"). These Funds were part of the ten thousand USD funds that TD Media LLC received from a third party named Organized Noise LLC who did not receive the Funds directly or indirectly from the Issuer and does not own st-ock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices. Neither SWN Media LLC, TD Media LLC and their member own shares of (VNRX:US). Please see important disclosure information here: https://stockwirenews.com/disclosure/vnrx-zvzos/#details

SWN Media | 4808 NW 2nd Ave Unit #388 | Boca Raton, FL 33431 US Unsubscribe | Update Profile | Constant Contact Data Notice